Bal Pharma Limited

01.04.2021

To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

BSE Limited
Mumbai.

Dear Sir,

Sub : Compliance with Regulation 30 of SEBI(SAST) Regulations ,2011.

With reference to the above, We are submitting to the exchanges disclosures received from promoters and PAC's of the Company for the financial year ended 31.3.2021, in compliance with Regulation 30 of SEBI (SAST) Regulations ,2011.

Please take the same on record.

Thanking You.

For Bal Pharma Limited

Authorised Signatory

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58
Email : info@balpharma.com Website : www.balpharma.com
CIN # L85110KA1987PLC008368
REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. : 41570813 / 19 Fax : 41570820

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or	NA		
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	SHAILESH SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	19,95,459	13.46%	12.81%
TOTAL	19,95,459	13.46%	12.81%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2021

SHAILESH SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

Shailesh Siroya

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (inclding that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or	NA		
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	ANITA SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	10,49,220	7.08%	6.73%
TOTAL	10,49,220	7.08%	6.73%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:
.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2021

Anita Siroya

ANITA SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

Anita Siroya

Anita Siroya

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.
3. Particulars of the Shareholders:	
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA
Or	
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	Dr.SUBBA RAO PRASANNA

4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	20,200	0.14%	0.12%
TOTAL	20,200	0.14%	0.12%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Prasanna

SUBBA RAO PRASANNA

Date: 31.03.2021

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2020.

Please take this intimation on record.

Thanking You.

Subba Rao Prasanna

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (inclding that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	SHRENIK D SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	0	0%	0%
TOTAL	0	0%	0%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Place: Bangalore

Date: 31.03.2021

SHRENIK D SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.



Shrenik D Siroya

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or	NA		
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	JIVI DHEERAJMAL SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	46,080	0.31%	0.29%
TOTAL	46,080	0.31%	0.29%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

JIVI D. SIROYA

Place: Bangalore

Date: 31.03.2021

JIVI DHEERAJMAL SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

JIVI D. SIROYA

Jivi Dheerajmal Siroya

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	CHANDRAPRAKASH DHEERAJMAL SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	4,86,420	3.28%	3.12%
TOTAL	4,86,420	3.28%	3.12%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date : 31.03.2021

CHANDRAPRAKASH DHEERAJMAL SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.



Chandraprakash Dheerajmal Siroya

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.
3. Particulars of the Shareholders:	
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (inclding that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	NA
Or	
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	ANITA CHANDRAPRAKASH SIROYA

4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of:			
a) Shares	1,22,687	0.83%	0.79%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	1,22,687	0.83%	0.79%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:
1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2021

ANITA CHANDRAPRAKASH SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.



Anita Chandraprakash Siroya

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA MICRO LABS LIMITED		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	13,10,836	8.84%	8.42%
TOTAL	13,10,836	8.84%	8.42%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

For MICRO LABS LIMITED

Place: Bangalore
Date: 31.03.2021

Gunjan Kumar Chaurasia
Company Secretary

MICRO LABS LTD. * BANGALORE *

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, We would like to confirm that we has not made any encumbrance on our shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

For Micro Labs Limited

Company Secretary

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA DILIP SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	4,74,994	3.20%	3.05%
TOTAL	4,74,994	3.20%	3.05%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:
1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2021

DILIP SURANA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

Dilip Surana

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA DILIP SURANA (HUF)		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	1,69,995	1.15%	1.09%
TOTAL	1,69,995	1.15%	1.09%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2021

DILIP SURANA (HUF)

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

Dilip Surana (HUF)

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA ANAND SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares.	% w.r.t. total share /voting capital wherever applicable.	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	5,25,686	3.55%	3.37%
TOTAL	5,25,686	3.55%	3.37%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2021

ANAND SURANA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

Anand Surana

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA ARCHANA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	2,84,996	1.92%	1.83%
TOTAL	2,84,996	1.92%	1.83%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2021

ARCHANA SURANA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

Archana Surana

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA MONICA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	1,79,909	1.21%	1.15%
TOTAL	1,79,909	1.21%	1.15%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2021

MONICA SURANA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

Monika Surana

C.C to The Chairman, Audit Committee